


Emerging concepts for web-based assessment of risk cohorts for Parkinson's disease

Alastair Noyce
Clinical Senior Lecturer

Preventive Neurology Unit
Wolfson Institute of Preventive Medicine
Barts and the London School of Medicine & Dentistry
Queen Mary University of London






NO CURE & NO DRUGS THAT CHANGE THE UNDERLYING DISEASE COURSE



VIEWPOINT

The Parkinson Pandemic—A Call to Action



Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

ANN NEUROL 2012


Alastair J. Noyce, BMedSci, MRCP,^{1,2} Jonathan P. Bestwick, MSc,³

Laura Silveira-Moriyama, PhD, MD,^{1,4} Christopher H. Hawkes, MD, FRCP,²

Gavin Giovannoni, PhD, FRCP,² Andrew J. Lees, MD, FRCP,¹ and Anette Schrag, PhD, FRCP¹



Barts and The London
School of Medicine and Dentistry



Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

ANN NEUROL 2012


Alastair J. Noyce, BMedSci, MRCP,^{1,2} Jonathan P. Bestwick, MSc,³

Laura Silveira-Moriyama, PhD, MD,^{1,4} Christopher H. Hawkes, MD, FRCP,²

Gavin Giovannoni, PhD, FRCP,² Andrew J. Lees, MD, FRCP,¹ and Anette Schrag, PhD, FRCP¹



Barts and The London
School of Medicine and Dentistry






OPEN ACCESS

REVIEW

The prediagnostic phase of Parkinson's disease

Alastair John Noyce,¹ Andrew John Lees,¹ Anette-Eleonore Schrag²






**Identification of risk and early features from
published evidence**



**Online population-based screening for these
factors**



Prospective follow-up



RISK KEY




High




Intermediate



Low



Opened 11th April 2011
~1500 individuals registered
1323 eligible and included





Movement disorders



OPEN ACCESS

RESEARCH PAPER

PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results

Alastair J Noyce,^{1,2} Jonathan P Bestwick,³ Laura Silveira-Moriyama,^{1,4} Christopher H Hawkes,² Charles H Knowles,² John Hardy,¹ Gavin Giovannoni,² Saiji Nageshwaran,⁵ Curtis Osborne,² Andrew J Lees,¹ Anette Schrag⁵

RESEARCH ARTICLE

PREDICT-PD: An Online Approach to Prospectively Identify Risk Indicators of Parkinson's Disease

Alastair J. Noyce, MRCP, PhD,^{1,2} Lea R'Biho, MSc, MRes,¹ Luisa Peress, BSc,² Jonathan P. Bestwick, MSc,³ Kerala L. Adams-Carr, MB, BS, BA,^{1,4} Niccolo E. Mancacci, MD,¹ Christopher H. Hawkes, FRCP, MD,² Joseph M. Masters, BSc,² Nicholas Wood, FRCP, PhD,¹ John Hardy, PhD,¹ Gavin Giovannoni, FRCP, PhD,⁵ Andrew J. Lees, FRCP, MD,¹ and Anette Schrag, FRCP, PhD^{1*}

TABLE 2. Longitudinal associations of baseline risk scores with UPSIT, RBDSQ, and tapping speed at year 3

	Higher risk	Lower risk	P value ^a
UPSIT score			
n	130	132	
Median (IQR)	30 (26-33)	33 (30-35)	<.001
<27 (%)	40 (31)	15 (11)	<.001
RBDSQ score			
n	140	139	
Median (IQR)	2 (1-4)	1 (0-3)	<.001
>5 (%)	33 (24)	10 (7)	<.001
KS score			
n	135	130	
Mean (95% CI)	51.3 (49.5-53.2)	55.5 (53.6-57.4)	.001
<44 (%)	40 (30)	17 (13)	.002

Every year participants asked for **new diagnosis of PD or movement disorder** (drug lists too).

Independent specialist diagnoses.

Positive answers followed up by **telephone** and **in-person visit**.

3 at year 1 1 at year 2 3 at year 3
7 in total

Baseline risk score and incident PD over 3 years
Hazard Ratio = 4.39 (95% CI 1.03-18.68; p=0.045)



[Home](#) [About The Study](#) [Who We Are](#) [Take Part](#)



Take part

Parkinson's is on the rise.

We need healthy people aged 60-80 years to help us PREDICT-PD and get closer to a cure.

FIND OUT MORE






Pre-Motor Parkinson's disease?

When Did Ray Kennedy's Parkinson's Disease Begin?

A. J. Lees

Department of Neurology, The Middlesex Hospital, Mortimer Street, London, U.K.



How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder

R. B. Postuma,^{1,2} A. E. Lang,³ J. F. Gagnon,^{2,4} A. Pelletier^{1,5} and J. Y. Montplaisir^{2,6}

Prediagnostic presentations of Parkinson's disease in primary care: a case-control study

Anette Schrag, Laura Horsfall, Kate Walters, Alastair Noyce, Irene Petersen





Subtle motor disturbances in PREDICT-PD participants


Alastair J Noyce,^{1,2} Anette Schrag,³ Joseph M Masters,² Jonathan P Bestwick,⁴
Gavin Giovannoni,² Andrew J Lees¹



Table 2 Comparison of total motor MDS-UPDRS scores and MoCA scores, and proportion of participants meeting three definitions of mild parkinsonian signs, between higher and lower risk participants

n	Higher risk 74	Lower risk 111	p Value
Median MDS-UPDRS (IQR)	3 (1.0–5.5)	1 (0.0–3.0)	<0.001
Mild parkinsonism Berg definition n (%)	13 (17.6%)	7 (6.3%)	0.027
Mild parkinsonism Louis definition n (%)	23 (31.1%)	12 (10.8%)	0.001
Global impression n (%)			
0–1.0	55 (74.3%)	103 (92.8%)	
1.5–2.5	17 (23.0%)	7 (6.3%)	0.001
3+	2 (2.7%)	1 (0.9%)	
Median MoCA (IQR)	27 (26–28)	28 (26–29)	0.049

MDS-UPDRS, Movements Disorders Society Unified Parkinson's Disease Rating Scale;
MoCA, Montreal Cognitive Assessment.



Motor prodrome:

- Follow up of participants seen in person
- Progression on BRAIN tapping test
- Wearable devices – PKG



BRAIN test



Barts and The London
School of Medicine and Dentistry

predictpd.com

Home Login

BRAIN TEST

Login
Forgotten password

Patient login

Please enter your access token

Please enter your access token

LOGIN

Clinician login

Email address

Please write in the box

Password

Password

LOGIN

predictpd.com

Left hand practice test

BACK TO INSTRUCTIONS


When you are ready, please start the practice by pressing the "S" key

00:10

S !

PREDICT-PD © 2018

Contact us | Follow us | AAH Software Ltd.







Brief Report | Open Access

Dopamine reuptake transporter–single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease

Alastair J. Noyce MRCP, PhD, John Dickson PhD, Richard N. Rees MRCP, Jonathan P. Bestwick MSc, Ioannis U. Isaías MD, PhD, Marios Politis MD, PhD, Gavin Giovannoni FRCP, PhD, ... [See all authors](#) ▾



Factor	Higher risk	Lower risk	P value
n	23	23	
Median age in years (IQR)	74.5 (69.7-78.9)	68.3 (66.7-71.1)	.003*
Males (%)	23 (100)	16 (70)	.009**
Median risk (odds 1/x and IQR)	5.5 (3.1-7.9)	105 (43-189)	<.001*
Mean worst SBR (95% CI)	2.6 (2.5-2.8)	2.9 (2.7-3.0)	.071***
Mean SN-max (95% CI)	0.22 (0.19-0.26)	0.14 (0.12-0.17)*	<.001***



Other prediction strategies are available...

REVIEW

CME

MDS Research Criteria for Prodromal Parkinson's Disease

Daniela Berg, MD,^{1*} Ronald B. Postuma, MD, MSc,^{2*} Charles H. Adler, MD, PhD,³ Bastiaan R. Bloem, MD, PhD,⁴

RESEARCH ARTICLE



CME

Validation of the MDS Research Criteria for Prodromal Parkinson's Disease: Longitudinal Assessment in a REM Sleep Behavior Disorder (RBD) Cohort

Seyed-Mohammad Fereshtehnejad, MD, MPH, PhD,^{1,2} Jacques Y. Montplaisir, MD, PhD,^{3,4} Amélie Pelletier, PhD,⁵
Jean-François Gagnon, PhD,^{3,6} Daniela Berg, MD,^{7,8} and Ronald B. Postuma, MD, MSc^{1,3*}

Prodromal Parkinson's Disease as Defined per MDS Research Criteria in the General Elderly Community

Philipp Mahlknecht, MD, PhD,^{1,2} Arno Gasperi, MD,³
Peter Willeit, MD, PhD,^{1,4,5} Stefan Kiechl, MD,¹
Helke Stockner, MD,¹ Johann Willeit, MD,¹
Gregorio Rungger, MD,³ Martin Sawires, MD,¹
Michael Nocker, MD,¹ Verena Rastner, MD,¹
Katherina J. Mair, MD,¹ Anna Hotter, MD,¹
Werner Poewe, MD,^{1*} and Klaus Seppi, MD^{1*}





Other web-based initiatives



Vision in
Parkinson's




23andMe



FOX
INSIGHT

YOUR EXPERIENCE FUELING RESEARCH



<https://vision-in-parkinsons.co.uk/>

Assessments

Clinical questionnaire

Do you suffer from any of the following:



Tremor



Visual hallucinations



Memory problems

Is your tremor worse at rest or when you try to do things?

Rest

In Action

Online visual acuity



Tapping test



Local group

n = 54
PD = 31
Controls = 23


Web-based group

n = 312
PD = 60
Controls = 252

Total

n = 366
PD = 91
Controls = 275


Cats & Dogs




Find the horses




Circles illusion




Biological motion




Snap



Match the grid







Controls: n=275
Parkinson's n= 91




Number horses found

20
15
10
5
0



Longitudinal study of visuo-perception in large numbers with genetic and clinical modifiers

- ~30 sites collecting data
- 224 participants taken part around the UK
- Target: 900 by December 2019



<https://vision-in-parkinsons.co.uk>





Remote assessment of Parkinsonism supporting ongoing development of intervention (Rapsodi)

- Longitudinal cohort study of glucocerebrosidase mutations (GBA) carriers without Parkinson disease
- GBA carriers drawn primarily from the pedigree of GBA PD cases and those with Gaucher disease (homozygous GBA carriers)
- Yearly assessment of anxiety, mood, motor symptoms, smell, cognition with DNA collection
- All assessments online or by post

www.rapsodistudy.com



The screenshot shows the Rapsodi website homepage. At the top, there's a navigation bar with links: Home, About the study, Who we are, and My study. Below this, a welcome message states: 'Welcome to Rapsodi. Rapsodi is a pioneering study which uses the internet to find new ways of diagnosing Parkinson's earlier to develop life changing treatments.' A section titled 'What is Rapsodi?' explains the study's purpose: 'Research has shown us that we may be able to intervene many years before people develop Parkinson's to stop it in its tracks. The GBA gene, which is carried by people with Gaucher disease, has been providing some unique insights into why people might develop Parkinson's disease.' A blue box highlights: 'If you have or are related to someone diagnosed with Gaucher disease or Parkinson's disease we'd like to hear from you.' A 'Take part in the study' button is present. The 'What the study involves' section lists six steps: 1. Register and log on, 2. It will take 45 minutes to an hour, 3. Fill in some questionnaires, 4. Do a keyboard tapping test, 5. Do some memory tasks, 6. We'll then send you a smell test and solve kit in the post. A 'Learn more' button is at the bottom. The footer includes a thank you message, a list of supporters (AUGL, health creatives, AAH SOFTWARE, PREDICTPD, CagTrack, PARKINSON'S, Gauchers ASSOCIATION, WITH PLYMOUTH UNIVERSITY), and a message from Parkinson's Research Scotland.

Slide provided by Stephen Mullin



23andMe

OUR SERVICE HOW IT WORKS STORIES BUY

SIGN IN REGISTER KIT HELP

23andMe

Welcome to you

saliva collection kit

Find out what your DNA says about you and your family.

- See how your DNA breaks out across 150+ regions worldwide
- Discover DNA relatives from around the world
- Share reports with family and friends

order now USD\$99



Cross-sectional data

- ~13,500 cases
- >3 million controls
- 840 available phenotypes (via questionnaire)
- DNA on all



New Results

The Parkinson's Phenome: Traits Associated with Parkinson's Disease in a Large and Deeply Phenotyped Cohort

Karl Heilbron, Alastair Noyce, Pierre Fontanillas, Babak Alipanahi, The 23andMe Research Team, Mike Nalls, Paul Cannon

doi: <https://doi.org/10.1101/270934>

This article is a preprint and has not been peer-reviewed [what does this mean?]



Previous

Posted February 28, 2018.

Download PDF

Email

Supplementary material





YOUR EXPERIENCE FUELING RESEARCH

To obtain comprehensive longitudinal data on over 100,000 individuals with PD in North America



Share Your Expertise

No one understands Parkinson's better than those living with it every day. By working together, we can help shape the future of research.



Participate Online

Fox Insight easily collects self-reported data about health experiences from those with and without Parkinson's in a number of ways.



Drive Genetic Insights

Eligible individuals can help researchers gain a holistic picture of the disease by participating in a genetic sub-study powered by 23andMe.

Join the **25713** participants helping to power Parkinson's research today.


Assessments:

- Motor symptoms
- Non motor symptoms
- Physical function
- Mental health
- Medications
- Quality of life
- Unmet needs
- Health care preferences

>10,000 in November 2017



>25,000 in October 2018



Genetic testing at no cost

Other remote sample collection



PARKINSON'S^{UK}
CHANGE ATTITUDES.
FIND A CURE.
JOIN US.



b+tlc BARTS
CHARITY



Barts and The London
School of Medicine and Dentistry

QMUL / BL SMD

Jack Cuzick

Gavin Giovannoni

Jonathan Bestwick

Ruth Dobson

Mark Jitlal

Polly Rawlinson

Stephen Auger

Josh Kahan

Charles Marshall

University of East Anglia

Carl Philpott

Guy's Hospital

Guy Leschziner

NIH

Sara Bandres-Ciga

Mike Nalls

Andy Singleton

UCL / NHNN / UCLH

Anette Schrag

Andrew Lees

John Hardy

Tom Warner

Sofia Eriksson

Anthony Schapira

Stephen Mullin

Maggie Burrows

John Dickson

Anna Nagy

Richard Rees

Theresita Joseph

Demis Kia

Kerala Adams-Carr

Nick Wood

Kemi Cracknell

Sebastian Schreglmann

Rimona Weil

23andMe

Karl Heilbron